List of Alphagan P drug patents

Alphagan P is owned by Allergan.

Alphagan P contains Brimonidine Tartrate.

Alphagan P has a total of 8 drug patents out of which 6 drug patents have expired.

Expired drug patents of Alphagan P are:

  • US9295641*PED
  • US6562873*PED
  • US9687443*PED
  • US6627210*PED
  • US6673337*PED
  • US6641834*PED

Alphagan P was authorised for market use on 16 March, 2001.

Alphagan P is available in solution/drops;ophthalmic dosage forms.

The generics of Alphagan P are possible to be released after 02 March, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295641

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(1 year, 17 days ago)

US6562873

(Pediatric)

ALLERGAN Compositions containing therapeutically active components having enhanced solubility
Jan, 2022

(1 year, 17 days ago)

US9687443

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(1 year, 17 days ago)

US6627210

(Pediatric)

ALLERGAN Compositions containing α-2-adrenergic agonist components
Jan, 2022

(1 year, 9 days ago)

US6673337

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(1 year, 1 day ago)

US6641834

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(11 months ago)

US8858961 ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Sep, 2023

(7 months from now)

US8858961

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Mar, 2024

(1 year, 1 month from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 16 March, 2001

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ALPHAGAN P before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic